5-item electronic questionnaire.
| Questions | Answers |
|---|---|
| 1. Have you visited a GP or hospital for bad asthma in last 12 months? | Yes* |
| No | |
| 2. How many times have you needed to use prednisone/prednisolone for your asthma in the last 12 months? | 0 |
| 1–2* | |
| ≥ 3* | |
| 3. How many reliever inhalers have you purchased in the last 12 months? | 0–2 |
| 3–5* | |
| ≥ 6* | |
| 4. During the last 7 days, how many times did you forget to take your usual asthma medication? | All the time^ |
| More than half the time^ | |
| Approximately half the time^ | |
| Less than half the time^ | |
| None | |
| 5. Have you seen your GP in last 4 weeks? | Yes* |
| No |
Note: * High risk of asthma exacerbation: Patients were identified at high risk of an asthma exacerbation in the last 12 months if they: 1) visit GP or hospital for bad asthma, OR; 2) used prednisone/prednisolone (i.e., OCS) for asthma flare-up, OR; 3) purchased 3 or more reliever inhalers (i.e., SABA). ^ Poor adherence to asthma medication: Patients who responded “All the time”, “More than half the time”, “Approximately half the time”, “Less than half the time”.
The supplementary tables for this article are available at: https://www.explorationpub.com/uploads/Article/file/1009134_sup_1.pdf.
SBA: Conceptualization, Methodology, Funding acquisition. SD: Writing—review & editing, Methodology, Investigation, Project administration. MdG: Data curation, Investigation, Software. RH: Formal analysis, Writing—original draft, Writing—review & editing, Visualization. BC: Writing—original draft, Writing—review & editing, Supervision, Project Administration. All authors read and approved the submitted version.
MdG has received non-financial support from NostraData for this manuscript. SBA has received honoraria for participation in expert advisory boards and given lectures for Teva Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Meda/Mylan, Sanofi, Mylan, Chiesi, Menarini, Sanofi, Boehringer Ingelheim, AbbVie and received unrestricted research grants from Mylan, AstraZeneca, Teva, AstraZeneca, GlaxoSmithKline, and Viatris. The other authors declare that they have no conflicts of interest.
This study was exempted from ethical review and meets the requirements set out in section 5.1.23 (b) of the National Statement on Ethical Conduct in Human Research 2007 (Updated 2018), which states that the institutions may choose to exempt from ethical review research that involves the use of existing collections of data or records that contain only non-identifiable data about human beings [31].
Informed consent to participate in the study was obtained from all participants.
Not applicable.
Original source data cannot be made publicly available because it belongs to ReCare and all data relevant to the manuscript has been included in the results section.
This work was supported by the Investigator Sponsored Study IIS GSK 213524/11035. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2026.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.